Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.50 |
| ▸ | IGF1R | P08069 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | XBP1 | P17861 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | NT5E | P21589 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14435461 | 0.86 | IGF1R (0.44) | MAOBIGF1RALOX5ALDH1A1HPGD | |
| SCHEMBL4073057 | 0.81 | MAOB (0.41) | MAOBALOX5 | |
| SCHEMBL4074309 | 0.81 | S1PR1 (0.41) | MAOBALOX5KMT2A | |
| SCHEMBL12575452 | 0.78 | BRD4 (0.47) | ALDH1A1HPGDKMT2ANT5E | |
| SCHEMBL4141765 | 0.77 | BRD4 (0.47) | — | |
| SCHEMBL31541596 | 0.77 | PIM1 (0.61) | — | |
| SCHEMBL4197723 | 0.77 | MAPK14 (0.44) | IGF1RALOX5ALDH1A1HPGDXBP1 | |
| SCHEMBL4127757 | 0.76 | PTGER1 (0.46) | — | |
| SCHEMBL1284047 | 0.76 | KDM4E (0.47) | ALDH1A1 | |
| SCHEMBL32665199 | 0.76 | KDM4E (0.50) | ALDH1A1HPGDKMT2ANPSR1NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557797-B2 | Triazolopyridine derivatives and their therapeutic use | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-10-15 | — | — | US | disclosed |
| US-20120088763-A1 | TRIAZOLOPYRIDINE DERIVATIVES AND THEIR THERAPEUTIC USE | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-04-12 | — | — | US | disclosed |
| US-20090012079-A1 | Triazolopyridine Compounds | LEWTHWAITE RUSSELL ANDREW | 2009-01-08 | — | — | US | disclosed |
| US-20090012079-A1 | Triazolopyridine Compounds | LEWTHWAITE RUSSELL ANDREW | 2009-01-08 | — | — | US | disclosed |
| EP-1984363-A1 | TRIAZOLOPYRIDINE COMPOUNDS | Pfizer Limited (GB) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007091152-A1 | TRIAZOLOPYRIDINE COMPOUNDS | PFIZER LIMITED (GB) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012079-A1 | Triazolopyridine Compounds | MAPKAPK5, MAPK1, MAPK4 | MAOB 988/4885IGF1R 4087/4885ALOX5 2585/4885 |
| US-20120088763-A1 | TRIAZOLOPYRIDINE DERIVATIVES AND THEIR THERAPEUTIC USE | CNKSR1, MOK, MAPK1 | MAOB 1551/4885IGF1R 2254/4885ALOX5 2288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.